Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Expand chart
Data: Google Trends; Chart: Jared Whalen/Axios

Full FDA approval of the Pfizer vaccine appeared to drive an uptick in intent about getting vaccinated, though it wasn't as impactful as the COVID-19 surge or vaccine mandates, Google Trends data suggests.

Why it matters: The FDA approval is one of the last levers the Biden administration has been hoping would prod the vaccine-hesitant.

By the numbers: U.S. searches for "how to get covid vaccine" rose 13% in the week the FDA approved the Pfizer jab, compared to the week before, according to Google Trends.

  • The searches increased 76% on Aug. 23, the day the FDA announced the decision, and peaked two days later before trending back down.

Yes, but: Google searches for getting the vaccine don't mean those users actually went to get the shot.

  • CDC data shows that the 7-day average for doses administered increased 5% that week.

The big picture: The spike was still less pronounced than the first week in August, when cases were surging and the U.S. hit a turning point with governments and employers embracing vaccine mandates.

Between the lines: The low point of Google searches to get the vaccine in late June coincided with the low watermark for new reported COVID cases in the U.S.

What's to watch: Full approval for the Moderna and Johnson & Johnson vaccines could trigger future spikes, but the impact is not likely to exceed the interest that followed Pfizer's green light.

Go deeper

Oct 14, 2021 - Health

Moderna has become the world's vaccine boogeyman

Illustration: Sarah Grillo/Axios

Moderna is under fire for not doing enough to vaccinate the world, particularly low-income countries — and the Biden administration is being criticized for not doing enough to force Moderna's hand.

Why it matters: Low-income countries are desperate for more vaccine, and experts warn that higher levels of global spread will increase the likelihood of a vaccine-resistant variant emerging.

Oct 14, 2021 - Health

FDA will review Merck COVID-19 pill

The Merck logo. Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images.

The U.S. Food and Drug Administration announced on Thursday that it will meet on Nov. 30th to review Merck's experimental oral antiviral COVID-19 treatment

Why it matters: An oral antiviral drug designed to prevent or treat COVID-19 could be a key tool to combat the pandemic. Merck ended its vaccine development in January.

Oct 14, 2021 - Podcasts

Clearing up the latest confusion around boosters

New data from the National Institutes of Health shows that people who got the Johnson & Johnson vaccine might benefit from getting a Pfizer or Moderna booster shot. But J&J has asked the FDA to approve a second shot for its own vaccine.

  • Plus, Miya Marcano and new attention on missing and murdered women of color.
  • And, Snapchat is trying to get its users to run for office.

Guests: Axios' Caitlin Owens and Alexi McCammond, and attorney Marlon Hill.

Credits: Axios Today is produced in partnership with Pushkin Industries. The team includes Niala Boodhoo, Sara Kehaulani Goo, Dan Bobkoff, Alexandra Botti, Nuria Marquez Martinez, Sabeena Singhani, Alex Sugiura, Lydia McMullen-Laird, Michael Hanf, and David Toledo. Music is composed by Evan Viola. You can reach us at podcasts@axios.com. You can text questions, comments and story ideas to Niala as a text or voice memo to 202-918-4893.

Go deeper: